Company: ANIX
Filing Date: 2025-09-10
Form Type: 10-Q
Source: 0001493152-25-013000
Chunk: 22

Company: Anixa Biosciences Inc
Filing Date: 2025-09-10
Form: 10-Q
Item: Part I, Item 1
Chunk 22
---
 employees purchased
1,518 shares and 2,616 shares, respectively, under the ESPP with aggregate proceeds of approximately $4,000 and $7,000, respectively
.

Warrants

As
of July 31, 2025, we had warrants outstanding to purchase 300,000 shares of common stock at $6.56 per share, issued during fiscal year
2021 and expiring on March 22, 2026.

Information
regarding the Company’s warrants for the nine months ended July 31, 2025 is as follows:

 SCHEDULE OF WARRANTS ACTIVITY

    Shares  
    Weighted
    Average Exercise Price Per Share  
    Aggregate
     Intrinsic  Value 
  
    Warrants
    outstanding at October 31, 2024 
     300,000  
    $6.56  

    Warrants
    outstanding and exercisable at July 31, 2025 
     300,000  
    $6.56  
    $0 

    12

The
following table summarizes information about the Company’s outstanding and exercisable warrants as of July 31, 2025:

 SCHEDULE OF OUTSTANDING AND EXERCISABLE WARRANTS

    Range
    of  Exercise Prices  
    Number
     Outstanding and  Exercisable  
    Weighted
    Average  Remaining  Contractual Life  (in years)  
    Weighted
     Average  Exercise Price 
  
    $6.56  
     300,000  
     0.6  
    $6.56 

Stock
Awards

During
the three and nine months ended July 31, 2025, we did not issue any stock awards. During the three and nine months ended July 31, 2024,
we issued 60,000 shares and 89,336 shares of common stock, respectively, to consultants providing investor relations services, and recorded
expense of approximately $62,000 and $158,000, respectively.

Treasury
stock

During
the fiscal year ended October 31, 2024, the Company purchased 2,000 shares of its common stock as treasury stock. The shares were purchased
at an average cost of $3.17 per share for a total cost of approximately $6,000. The repurchases were made as part of a stock buyback
program approved by our Board of Directors